# A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer

> **NCT05619172** · PHASE2 · TERMINATED · sponsor: **SOTIO Biotech AG** · enrollment: 16 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Nanrilkefusp alfa
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT05619172
- **Lead sponsor:** SOTIO Biotech AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-12-22
- **Primary completion:** 2024-03-06
- **Final completion:** 2024-06-05
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Due to lack of efficacy shown at the time of the interim analysis.
- **Last updated:** 2025-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05619172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05619172, "A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05619172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*